Literature DB >> 20032104

Linkage and association studies of joint morbidity from rheumatoid arthritis.

Jin-Young Min1, Kyoung-Bok Min, Joohon Sung, Sung-Il Cho.   

Abstract

OBJECTIVE: To investigate the relationship between genetic variations of rheumatoid arthritis (RA) susceptibility in terms of joint morbidity.
METHODS: We used data from Genetic Analysis Workshop 15. The Illumina linkage panel IV included 5858 single-nucleotide polymorphisms (SNP), with 5744 SNP passing quality control filters. The phenotypic variables analyzed were the level of rheumatoid factor (RF) and score on the Joint Alignment and Motion (JAM) scale. We modified the scale, dividing by RF values relevant to disease severity. Linkage analysis for affected sibling pairs was done using the MERLIN program, and family-based association tests were carried out using PLINK and FBAT software.
RESULTS: We found a high peak (LOD = 3.29; NPL Z = 4.07) near the HLA-DRB1 region on chromosome 6. The linkage at 6p24 at rs1410766 [LOD = 2.66; nonparametric linkage (NPL) Z = 3.23] was statistically significant. Two other regions also showed possible linkage peaks: chromosome 7q30 at rs322812 (LOD = 2.47; NPL Z = 3.39) and chromosome 15p34 at rs347117 (LOD = 1.95; NPL Z = 2.80). For the family-based association study, 7 SNP related to clinical RA severity were detected.
CONCLUSION: Genetic variations may lead to an enhanced risk of joint damage and increased levels of RF. Further studies are needed to elucidate the roles of other genes involved in RA and to explore whether the clinical signs of RA are associated with particular genetic variations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20032104     DOI: 10.3899/jrheum.090526

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  1 in total

1.  Powerful haplotype-based Hardy-Weinberg equilibrium tests for tightly linked loci.

Authors:  Wei-Gao Mao; Hai-Qiang He; Yan Xu; Ping-Yan Chen; Ji-Yuan Zhou
Journal:  PLoS One       Date:  2013-10-22       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.